Cadrenal Therapeutics (CVKD) CEO Quang Pham Sells $13K of Stock

Quang Pham, the Chairman, CEO, and Interim CFO of CVKD, sold 3,666 shares of the company on June 15, 2026. The shares were sold at an average price of $3.58, totaling $13,124.28. This transaction was not part of a pre-planned trading program.

Other Institutional Activity in CVKD

Vanguard Capital Management LLC significantly increased its position in CVKD, adding 45,201 shares to hold a total of 45,201 shares valued at approximately $231,429. Geode Capital Management, LLC also boosted its holdings by 7,098 shares, reaching a total of 21,626 shares worth about $110,724. Vanguard Fiduciary Trust Co acquired 8,311 shares, bringing its total to 8,311 shares valued at $42,552. Meanwhile, BlackRock, Inc. increased its stake by 1,974 shares to 5,496 shares, valued at $28,140.

Cadrenal Therapeutics, Inc. Stock Up 211.2%

Shares of CVKD traded around $3.33 recently. The stock has experienced insider sales at varied prices, with some transactions occurring at prices as high as $4.38 per share.

Insider Buying and Selling at Cadrenal Therapeutics, Inc.

Quang Pham has been actively selling shares of CVKD. Apart from the June 15 transaction, he sold 12,996 shares on June 12 at $3.94 each, and 1,462 shares on June 11 at $4.12 each. Earlier, on June 10, he sold 3,500 shares at $4.21, part of a planned sale. On June 9 and June 8, he sold 12,992 and 5,893 shares at $4.06 and $4.38, respectively, both under planned sales.

Analysts Set New Price Targets

On April 7, 2026, HC Wainwright & Co. maintained a 'buy' rating on CVKD with a $13.00 price target. This follows a series of 'buy' ratings by the firm, including a reiterated target of $32.00 in May 2025. Noble Financial also maintained a 'buy' rating with a $4.00 target on March 13, 2024.

Bottom Line

Quang Pham's recent sales of CVKD shares offer insight into insider activity at the company. Investors might keep an eye on these insider transactions for potential implications. Institutional interest in CVKD remains strong, with notable increases from several major funds. Analyst ratings continue to reflect a positive outlook, though it's important to remember that these reports are retrospective and may not reflect current positions.